Experimental treatment for pancreatic cancer could be breakthrough for patients
Deneysel bir mRNA aşısı, Memorial Sloan Kettering'de pankreas kanserine karşı kişiselleştirilmiş olarak ilk kez kullanılmış ve hastanın altı yıldır kansersiz kaldığı görülmüştür.
An experimental personalized mRNA vaccine for pancreatic cancer is demonstrating significant potential, according to new data. The treatment has shown promising results, with one patient who received it as part of a trial at Memorial Sloan Kettering remaining cancer-free for six years. This innovative approach involves tailoring the vaccine specifically to an individual's tumor.
Researchers are optimistic about this development, which could represent a major advancement in treating a notoriously difficult-to-treat cancer. The vaccine works by training the patient's immune system to recognize and attack cancer cells.
This experimental treatment offers a new ray of hope for pancreatic cancer patients, a disease with historically low survival rates.
📌 Kaynak
Bu özet nbcnews kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →